http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-371455-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bba842fc4d37dfcaced1b55bc0c91c7c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-02 |
| filingDate | 1969-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1972-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-371455-A1 |
| titleOfInvention | PROCEDURE FOR OBTAINING PYRACINE DERIVATIVES. |
| abstract | The invention comprises novel derivatives of octahydro - 8H - oxazolo[3,2 - a]pyrrolo[2,1 - c]- pyrazine of the general Formula I wherein x y is or R 1 is H or CH 3 and R 2 is isopropyl or isobutyl with the proviso that when R 1 is H and R 2 is isopropyl, x y is only and the acid addition salts thereof, which are prepared by reacting a novel acid addition salt of a compound of general Formula II obtained either by heating (2R, 5S, 10aS, 10bS)- 2 - azidocarbonyl - 2 - ethyl - 5 - isopropyl (or isobutyl) - 3,6 - dioxo - 10b - hydroxy - octahydro- 8H - oxazolo[3,2 - a]pyrrolo[2,1 - c] - pyrazine prepared by reacting the corresponding 2- chloroformyl derivatives with sodium azide, or by splitting off the benzyloxycarbonyl radical from the novel (2R, 5S, 10aS, 10bS) - 2 - benzyloxycarbonylamino - 2 - ethyl - 5 - isopropyl (or isobutyl) - 3,6 - dioxo - 10b - hydroxy - octahyrdo- 8H - oxazolo[3,2 - a]pyrrolo - [2.1 - c]pyrazine, resulting from the reaction of the above azidocarbonyl derivatives with benzyl alcohol at an elevated temperature, with a reactive functional derivative of the appropriate lysergic acid in a solvent or solvent mixture in the presence of a basic condensation agent or by hydrogenating the corresponding compounds of the general Formula I in which x y is or by methylating the corresponding compounds of the general Formula I in wherein R 1 is H. (2R, 5S, 10aS, 10bS) - 2 - Carboxy - 2 - ethyl- 5 - isopropyl (or isobutyl) - 3,6 - dioxo - 10b - hydroxy - 8H - oxdzolo[3,2 - a]pyrrolo[2,1 - c]pyrazine is made by hydrolysing the corresponding 2 - ethoxycarbonyl derivative resulting from the hydrogenation of (3S,8aS,[alpha]S) - 2 - ([alpha] - ethoxycarbonyl - [alpha] - benzyloxybutyoyl) - 3 - isopropyl (or isobutyl) - 1,4 - dioxo - octahydro - pyrrolo[1,2- [alpha]]pyrazine, obtained by reacting (3S, 8aS) - 1,4- dioxo - 3 - isopropyl (or isobutyl) - octahydropyrrolo [1,2-a] pyrazine with S(+ )-2-ethyl-2- benzyloxy-malonic acid chloride monoethyl ester, resulting from the reaction of thionyl chloride with the corresponding malonic acid monoethyl ester, which is in turn prepared by reacting the racemic compound with cinchonidine, separating the mixture of salts thus obtained, and decompositing the cinchonidine salt of (+ )-2- ethyl - 2 - benzyloxy-malonic acid monoethyl ester. Racemic 2 - ethyl - 2 - benzyloxy - malonic acid monoethyl ester is obtained by saponification of the corresponding diethyl malonate, which is prepared either by reacting diethyl 2-ethyl-2- hydroxy-malonate with benzyl chloride or diethyl 2-benzyloxymalonate with sodium ethylate. Pharmaceutical compositions, suitable for oral, enteral, or parenteral administration, and having anti-serotonin and/or salidiuretic effects, contain the above novel compounds of Formula I above or pharmaceutically acceptable acid addition salts thereof and carriers or diluents. Reference has been directed by the Comptroller to Specification 1,011,113. |
| priorityDate | 1967-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.